

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_79466
Title of the Manuscript:	A brief review on Viral Variants of Covid 19 infection
Type of the Article	REVIEW

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p>	<p>I am honoured to review the manuscript Number: "Ms_JPRI_79466" entitled "A brief review on Viral Variants of Covid 19 infection" for the "Journal of Pharmaceutical Research International".</p> <p>The authors presented a very interesting manuscript about the various variants of COVID-19. However, there are many errors and major revisions that the authors should do to merit publication in this journal.</p> <ol style="list-style-type: none"> 1) Please write COVID-19 it's not covid 19 or Covid 19 or COVID 19, even in the title! Please use "COVID-19" from the start until the end of the paper. 2) Please add a part where you study the new variant 'omicron' coronavirus. 3) There are some Run-on sentences, here are some examples of sentences to rephrase: <ul style="list-style-type: none"> • "The wild type virus mutated soon after a new strain emerged it contained a 29 nucleotide deletion in orf8 dubbed 29 following that a deletion of 82 nucleotides and 415 nucleotides in the same area were discovered" • "promotes immunological evasion by downregulating mhc i molecules according to a recent study" • "Pcr samples without the s gene were utilised to define variant b 1 1 7 there are 17 mutations in the viral genome of b 1 1 7" • "Has ten mutations l18f t20n p26s d138y r190s h655y t1027i v1176 k417t e484k and n501y rbd has three mutations l18f k417n and e484k which are identical to variation b 1 351" • Characteristics of mutations with unique genetic markers epsilon b 1 427 and b 1 429 zeta p 2 eta b 1 525 theta p 3 iota b 1 526 kappa b 1 617 1 and lambda b 1 617 1 • re the seven variations of interest voi described in the who weekly epidemiological report on june 22 2021 c 37 around june 2020 epsilon b 1 427 and b 1 429 variants commonly known as cal 20c/l452r • Specific mutations can be found in these versions b 1 427 l452r d614g b 1 429 s13i w152c l452r d614g the cdc has designated this strain as a variation of concern in the united states due to its high transmissibility 4) At the same time, there are some English errors, typos and grammatical mistakes, I advice you to make a round of revisions, please consider making your paper revised by a native English or even a Specialist. 5) There are some interesting papers that you did not cite, here are some examples of papers to add: <p>In Alpha variant, please specify that it can be especially harmful for people suffering from comorbiteis, diabetes and rheumatic diseases and add this reference:</p> <ul style="list-style-type: none"> • Aouissi, H. A., & Belhaouchet, I. (2021). What about rheumatic diseases and COVID-19?. New microbes and new infections, 41, 100846. https://doi.org/10.1016/j.nmni.2021.100846 <p>In Delta variant, consider also adding this manuscript:</p> <ul style="list-style-type: none"> • Shiehzaadegan, S., Alaghemand, N., Fox, M., & Venketaraman, V. (2021). Analysis of the Delta Variant B.1.617.2 COVID-19. Clinics and practice, 11(4), 	

Review Form 1.6

	<p>778–784. https://doi.org/10.3390/clinpract11040093 Please add more details about the effect of Chinese vaccines, especially sinovac, and cite these 2 papers:</p> <ul style="list-style-type: none"> • Tao, Y. Y., Li, J. X., Hu, Y. M., Hu, Y. S., Zeng, G., & Zhu, F. C. (2021). Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis. <i>Expert review of vaccines</i>, 20(1), 1–11. https://doi.org/10.1080/14760584.2021.1875823 • Palacios, R., Patiño, E. G., de Oliveira Piorelli, R., Conde, M., Batista, A. P., Zeng, G., Xin, Q., Kallas, E. G., Flores, J., Ockenhouse, C. F., & Gast, C. (2020). Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i>, 21(1), 853. https://doi.org/10.1186/s13063-020-04775-4 <p>6) Please try to change the way you have done your aim and objective, try to put them in a single paragraph rather than in 2 small titles .</p>	
Minor REVISION comments	<p>1) Concerning references, as it is a review article, please try to add more papers, approximately 10 others to make your review stronger. 2) Consider also adding information about the selection of the articles in your review. 3) Please Consider the fact of adding a prisma flow chart</p>	
Optional/General comments	<p>Have you checked that the review is original?</p>	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Hani Amir Aouissi
Department, University & Country	Center Scientific Research And Technical Sur Les Régions Aride, Algeria